Ventricular Assist Devices (VAD)

This channel includes news and new technology innovations for ventricular assist devices (VAD). VADs are a type of mechanical hemodynamic support device that helps increase blood flow in people who have ventricles that are not work properly due to heart failure, cardiogenic shock, cardiomyopathy or myocardial infarction. Most often these devices support the left ventricle, so they are often referred to as left ventricular assist devices (LVAD). VADS come in two types, surgically implanted, usually as a bridge to heart transplant, and percutanenous catheter-based pumps used for temporary hemodynamic support. Examples of temporary percutaneous pumps include the Impella and TandemHeart devices.

 

CMS coverage changes effective as of Dec. 2, 2020 will open up the use of LVADs to more Medicare patients, including use of the HeartWare and HeartMate ventricular assist devices.

CMS coverage changes effective as of Dec. 2, 2020 will open up the use of LVADs to more Medicare patients, including use of the HeartWare and HeartMate ventricular assist devices.

News | Heart Failure | December 02, 2020
December 2, 2020 — The Centers for Medicare and Medicaid Services (CMS) finalized updates to Medicare coverage policies...
Videos | Hemodynamic Support Devices | October 20, 2020
Chuck Simonton, M.D., chief medical officer at Abiomed, discusses some of the new technologies and clinical trials the...
The Abiomed Impella was highlighted in several sessions at the 2020 TCT Connect conference. #TCT #TCT2020 #TCTconnect
News | Hemodynamic Support Devices | October 16, 2020
October 16, 2020 — The Restore EF Study demonstrates the use of contemporary best practices, including attempting a...
The Medtronic Heartware and Abbott Heartmate 3 LVADs and others currently cleared by the FDA might be easier to use in Medicare advanced heart failure patients under new guidelines proposed by CMS. Photo by Dave Fornell

The Medtronic Heartware and Abbott Heartmate 3 LVADs and others currently cleared by the FDA might be easier to use in Medicare advanced heart failure patients under new guidelines proposed by CMS. Photo by Dave Fornell

Feature | Heart Failure | August 21, 2020 | Dave Fornell, Editor
August 21, 2020 — The U.S. Centers for Medicare and Medicaid Services (CMS) proposed updates to coverage policies for...
Abiomed Impella is now authorized to treat critical ICU COVID-19 patients on ECMO who develop pulmonary edema or need cardiac decompensation from myocarditis. #COVID19 #SARScov2 #Impella

Abiomed Impella is now authorized to treat critical ICU COVID-19 patients on ECMO who develop pulmonary edema or need cardiac decompensation from myocarditis.

Feature | Coronavirus (COVID-19) | August 05, 2020 | Dave Fornell, Editor
August 5, 2020 — The U.S. Food and Drug Administration (FDA) issued an emergency use authorization (EUA) this week for...
Abiomed announced the U.S. Food and Drug Administration (FDA) has approved the company's investigational device exemption (IDE) application to start an early feasibility study with a first-in-human trial of the 9 French (Fr) Impella ECP heart pump. Impella ECP, which stands for "expandable cardiac power," will be studied in high-risk percutaneous coronary intervention (PCI) patients.
News | Hemodynamic Support Devices | June 05, 2020
June 5, 2020 — Abiomed announced the U.S. Food and Drug Administration (FDA) has approved the company's investigational...
Videos | Hemodynamic Support Devices | June 05, 2020
This is a quick animation demonstrating how the new 9 French Abiomed Impella ECP expands to approximately 18 French and...
he U.S. Food and Drug Administration (FDA) has issued an emergency use authorization (EUA) for the Abiomed Impella RP catheter-based heart pump to include patients suffering from COVID-19 related right heart failure or decompensation, including pulmonary embolism (PE).  #COVID19 #SARScov2
Feature | Coronavirus (COVID-19) | June 01, 2020
June 1, 2020 — The U.S. Food and Drug Administration (FDA) has issued an emergency use authorization (EUA) for the...
FDA Class I Recall Issued for Medtronic HeartWare HVAD Pump
News | Ventricular Assist Devices (VAD) | May 29, 2020
May 29, 2020 — Medtronic is recalling its HeartWare HVAD left ventricular assist device (LVAD) pump outflow graft and...
News | Artificial Heart | May 27, 2020
May 27, 2020 — Carmat, a developer of the of a next generation advanced total artificial heart, announces the first...
News | Artificial Heart | March 10, 2020
March 10, 2020 —  The U.S. Food and Drug Administration (FDA) has cleared the SynCardia Systems 50cc temporary Total...
News | Heart Failure | March 05, 2020
March 5, 2020 — Abbott recently received Breakthrough Device designation from the U.S. Food and Drug Administration (...
he U.S. Food and Drug Administration (FDA) has approved Carmat's investigational device exemption (IDE) application to start a U.S. early feasibility study (EFS) of its total artificial heart.
News | Heart Failure | February 12, 2020
February 12, 2020 — The U.S. Food and Drug Administration (FDA) has approved Carmat's investigational device exemption...
Videos | Hemodynamic Support Devices | February 07, 2020
Interview with Navin Kapur, M.D., FAHA, FACC, FSCAI, executive director, The CardioVascular Center for Research and...